United Therapeutics CEO Executes Stock Sales and Option Exercise as Company Reports Phase 3 Success and $2B Buyback
United Therapeutics Chairperson and CEO Martine Rothblatt sold 9,440 shares of the company's common stock on March 13, 2026, for about $5.1 million, and exercised options to acquire 9,500 shares the same day. The transactions were carried out under a 10b5-1 trading plan adopted in November 2025. Separately, the company announced publication of its …